{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:25:23Z","timestamp":1773289523178,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,2]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Centrally mediated abdominal pain syndrome (CAPS) is characterized by severe abdominal pain. Diagnosis of CAPS is still an exclusionary diagnosis, there remain no effective diagnostic biomarkers so far. Duloxetine is the major pharmacotherapy of CAPS, while some CAPS patients do not respond to duloxetine treatment. However, there is a lack of molecular markers to predict the efficacy of duloxetine. In our pilot study, we have found differential expression profiles of serum miRNAs between CAPS patients and healthy controls. Our study aims to explore the clinical characteristics, specific miRNAs in serum as diagnostic biomarkers of CAPS and predictive biomarkers of the efficacy of duloxetine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/design:<\/jats:title>\n            <jats:p>In this prospective cohort study, we plan to enroll 430 participants including 215 CAPS patients and 215 healthy controls. The CAPS group takes duloxetine 30\u2009mg per day as an initial dose. Patients will have 24-week medication period and follow up at week 0, 4, 12, 24 and 36. Blood samples will be obtained from patients at every visits and health controls at the initial visit and a series of questionnaires will be completed by the participants. The primary end points are: The differential expression of miRNAs between CAPS groups and healthy control groups at baseline. The changes in abdominal pain scores before and after duloxetine treatment in patients with CAPS and their relationship with the changes in miRNAs. The secondary end point is the changes in scores of depression, anxiety, sleep quality and quality of life before and after duloxetine treatment in patients with CAPS and their relationship with changes in miRNAs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>Findings of study will provide the reliable basis for diagnosis and the predictor of duloxetine efficacy of CAPS. Importantly, findings grant patients a chance to benefit from treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032134","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T16:07:12Z","timestamp":1670515632000},"page":"e32134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of clinical characteristics of centrally mediated abdominal pain syndrome, exploration of diagnostic markers and its relationship with the efficacy of duloxetine treatment"],"prefix":"10.1097","volume":"101","author":[{"given":"Yuming","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiani","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hefeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2029-8831","authenticated-orcid":false,"given":"Duowu","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1053\/j.gastro.2016.02.034","article-title":"Centrally mediated disorders of gastrointestinal pain.","volume":"150","author":"Keefer","year":"2016","journal-title":"Gastroenterology"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"17562848211021717562848211021783","DOI":"10.1177\/17562848211021783","article-title":"Evaluation of the short-term efficacy of local analgesic (lidocaine) and opioid analgesic (sufentanil) on patients with centrally mediated abdominal pain syndrome: a randomized controlled trial.","volume":"14","author":"Yang","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.06.001","article-title":"MicroRNA and chronic pain: from mechanisms to therapeutic potential.","volume":"180","author":"Lopez-Gonzalez","year":"2017","journal-title":"Pharmacol Ther"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study.","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2036.2010.04561.x","article-title":"Review article: the functional abdominal pain syndrome.","volume":"33","author":"Sperber","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/nmo.12509","article-title":"Centrally targeted pharmacotherapy for chronic abdominal pain.","volume":"27","author":"Tornblom","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/apt.15241","article-title":"Chronic continuous abdominal pain: evaluation of diagnostic features, iatrogenesis and drug treatments in a cohort of 103 patients.","volume":"49","author":"Kilgallon","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jpain.2019.12.002","article-title":"Epigenetic and miRNA expression changes in people with pain: a systematic review.","volume":"21","author":"Polli","year":"2020","journal-title":"J Pain"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.3390\/ijms23116016","article-title":"Expression and biological functions of miRNAs in chronic pain: a review on human studies.","volume":"23","author":"Sabina","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpsychires.2018.12.007","article-title":"Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment.","volume":"110","author":"Kim","year":"2019","journal-title":"J Psychiatr Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances.","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.tibs.2012.08.003","article-title":"Extracellular miRNAs: the mystery of their origin and function.","volume":"37","author":"Turchinovich","year":"2012","journal-title":"Trends Biochem Sci"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1517\/14712598.2011.577060","article-title":"miRNA-based therapies for the irritable bowel syndrome.","volume":"11","author":"Zhou","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.bbrc.2019.02.126","article-title":"MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7.","volume":"511","author":"Zhu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1185\/03007995.2011.609540","article-title":"Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.","volume":"27","author":"Gaynor","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"15497","DOI":"10.1038\/ncomms15497","article-title":"MicroRNAs 146a\/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK\/Wnt-system genes.","volume":"8","author":"Lopez","year":"2017","journal-title":"Nat Commun"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:32:19Z","timestamp":1746333139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":17,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032134","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}